Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.
Shiyu JiangYan QinLin GuiPeng LiuHongxin JiangBiao LiuJianliang YangSheng YangXiaohui HeShengyu ZhouXinhua DuYuting YiJing LinYuan-Kai ShiPublished in: Targeted oncology (2020)
This study adds clinical observations with MYD88MUT patients, further helping to understand the genetic features and possible correlation of MYD88MUT with response to ibrutinib.
Keyphrases
- diffuse large b cell lymphoma
- toll like receptor
- end stage renal disease
- ejection fraction
- epstein barr virus
- newly diagnosed
- chronic kidney disease
- prognostic factors
- copy number
- chronic lymphocytic leukemia
- peritoneal dialysis
- high resolution
- gene expression
- immune response
- inflammatory response
- patient reported outcomes